etentamig + iberdomide

**Etentamig + iberdomide** is an investigational combination therapy for **relapsed/refractory multiple myeloma**. Etentamig is administered intravenously and is being developed as a novel therapeutic agent; its precise molecular target or mechanism is not disclosed in public sources, but it is being systematically tested for safety and efficacy in this combination. **Iberdomide** is an oral small molecule, part of the CELMoD (Cereblon E3 Ligase Modulator) class, which binds to cereblon (CRBN) and promotes the degradation of Ikaros (IKZF1) and Aiolos (IKZF3) transcription factors, modulating immune response and inhibiting myeloma cell growth. The combination is in early-phase clinical trials for adults with relapsed/refractory multiple myeloma, exploring dose escalation and safety[1][3][5][7][9].